FDA Approves New First-Line TNBC Regimen - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

  • By

  • Kathryn Wighton

  • June 26, 2026

  • 3 min

Share

Original Source(s)

FDA Approves New First-Line TNBC Regimen

  • by Kathryn Wighton

  • June 26, 2026

Related Content

Immune heterogeneity and therapeutic resistance in gynecological malignancies

Survival beyond treatment: patterns and determinants of disease-free survival in cervical cancer at a tertiary care center in India

FDA Approves Gedatolisib in Breast Cancer

In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.